Evaxion Biotech A/S (EVAX) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Horsholm, Denmark. The current CEO is Helen Katrina Tayton-Martin.
EVAX has IPO date of 2021-02-05, 46 full-time employees, listed on the NASDAQ Capital Marke, a market capitalization of $26.15M.
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.
